# First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation

> **NCT05939076** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Region Örebro County** · enrollment: 220 (estimated)

## Conditions studied

- Atrial Fibrillation, Persistent

## Interventions

- **DEVICE:** Pulmonary vein isolation
- **DRUG:** dronedarone - Multaq™ OR flecainide - Tambocor™ OR propafenone - Rytmonorm™ OR sotalol - Sotacor™

## Key facts

- **NCT ID:** NCT05939076
- **Lead sponsor:** Region Örebro County
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-08-21
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2023-07-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05939076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05939076, "First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05939076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*